Agafi Intravitreal 2 mg/0.05 ml is a Product of the Generic Aflibercept Intravitreal Injection

Agafi Intravitreal 2 mg/0.05 ml belongs to the generic category of Aflibercept Intravitreal Injection. This medicine should be used according to a doctor's advice. We have provided detailed information about the uses, dosage, effectiveness, side effects, precautions, drug interactions, storage conditions, and other important details of Agafi Intravitreal 2 mg/0.05 ml. Our goal is to present essential medicine information in one place for patients, caregivers, and healthcare professionals. To better understand Aflibercept Intravitreal Injection and ensure the safe use of this medicine, please read the information below carefully and consult a healthcare professional when necessary.

Description of Agafi Intravitreal 2 mg/0.05 ml

Agafi Intravitreal 2 mg/0.05 ml may be available as a prescription or over-the-counter medicine, depending on local regulations and medical recommendations. It is used for the treatment and management of specific conditions or symptoms. The way this medicine is used may vary depending on the patient's condition and the advice of a healthcare provider. Detailed information about the approved uses, therapeutic applications, and other relevant details of Agafi Intravitreal 2 mg/0.05 ml is provided below to help users gain a clear understanding of this medicine.

What Is Agafi Intravitreal 2 mg/0.05 ml Indications and Uses?

Agafi Intravitreal 2 mg/0.05 ml (Aflibercept Intravitreal Injection) Injection is indicated for adults for the treatment of- Neovascular (wet) age-related macular degeneration (AMD) Visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO) Visual impairment due to diabetic macular oedema (DME) Visual impairment due to myopic choroidal neovascularisation (myopic CNV)

Pharmacology (Source, Chemical and Physical Composition) Of Agafi Intravitreal 2 mg/0.05 ml

Agafi Intravitreal 2 mg/0.05 ml (Aflibercept Intravitreal Injection) is a recombinant fusion protein consisting of portions of human VEGF receptors 1 and 2 extracellular domains fused to the Fc portion of human IgG1 formulated as an iso-osmotic solution for intravitreal administration. Aflibercept is a dimeric glycoprotein with a protein molecular weight of 97 kilodaltons (kDa) and contains glycosylation, constituting an additional 15% of the total molecular mass, resulting in a total molecular weight of 115 kDa. Aflibercept is produced in recombinant Chinese hamster ovary (CHO) cells. Aflibercept acts as a soluble decoy receptor that binds VEGF-A and PlGF, and thereby can inhibit the binding and activation of these cognate VEGF receptors.

Side Effects of Agafi Intravitreal 2 mg/0.05 ml

The most common adverse reactions (≥5%) reported in patients receiving Agafi were conjunctival hemorrhage, eye pain, cataract, vitreous detachment, vitreous floaters, retinal pigment epithelial tear and intraocular pressure increased.

Precautions And Warnings for Agafi Intravitreal 2 mg/0.05 ml

Endophthalmitis, retinal pigment epithelial tear and retinal detachments may occur following intravitreal injections. Patients should be instructed to report any symptoms suggestive of endophthalmitis or retinal detachment without delay and should be managed appropriately. Increases in intraocular pressure have been seen within 60 minutes of an intravitreal injection. There is a potential risk of arterial thromboembolic events following intravitreal use of VEGF inhibitors

Use During Pregnancy and Lactation

Pregnancy : Adequate and well-controlled studies with Agafi Intravitreal 2 mg/0.05 ml (Aflibercept Intravitreal Injection) have not been conducted in pregnant women. Aflibercept produced adverse embryofetal effects in rabbits, including external, visceral, and skeletal malformations. Lactation : There is no information regarding the presence of aflibercept in human milk, the effects of the drug on the breastfed infant, or the effects of the drug on milk production/excretion. Females and Males of Reproductive Potential : Females of reproductive potential are advised to use effective contraception prior to the initial dose, during treatment, and for at least 3 months after the last intravitreal injection of Aflibercept. Infertility : There are no data regarding the effects of Aflibercept on human fertility

Therapeutic Class

Other ophthalmic preparations

Storage Conditions of It

Store at 2ºC to 8ºC in a refrigerator. Do not freeze. Keep away from light and out of the reach of children. Pack Image: Agafi 2 mg/0.05 ml Injection Thanks for using MedEx! How would you rate your experience so far?

Agafi Intravitreal 2 mg/0.05 ml is a Product of the Generic Aflibercept Intravitreal Injection